Revenue growth of 19% YoY and narrowed net loss are positive, but guidance was reiterated (not raised) and EPS was in line with consensus. The stock may trade on the Phase 3 ACCEL timeline (topline H2 2027) and any updates on IBSRELA's path to $1B annual revenue. Monitor upcoming patent issuance and payer access developments.
Drug in focus
ARDX drug pipeline →tenapanor
● Neutral Named in this press release- Impact
- Phase
- Approved (IBS-C and hyperphosphatemia); Phase 3 for CIC
- Time to market
- Already on the market for IBS-C (since 2021 launch) and hyperphosphatemia (since 2023 launch). CIC label expansion would be the next milestone, with data expected H2 2027 and potential FDA filing in 2028.
- Next catalyst
- None dated
What to watchTenapanor is a mature commercial asset with no near-term binary catalyst. Watch the Q4 2026 earnings (expected early 2027) for whether IBSRELA revenue growth stabilizes or continues decelerating. The Phase 3 ACCEL CIC readout in H2 2027 is the next major value-inflection point, but it is over 12 months away. In the meantime, payor access dynamics and prescription trends will drive the stock more than any single event.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $3.29entry
- T+1 · 12d ago −9.12%α −4.71% · $2.99
- T+5 · 6d ago −4.86%α −3.95% · $3.13
- T+9 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ardelyx reported Q3 2026 total product revenue of $125.5M, up 19% YoY, with IBSRELA growing 23% to $96.3M and XPHOZAH up 7% to $29.2M. Net loss narrowed to $0.7M ($0.00 per share) from $1.0M a year ago, in line with the consensus EPS estimate of -$0.02. The company reiterated full-year revenue guidance for both products and completed enrollment in the Phase 3 ACCEL trial for chronic idiopathic constipation.
Key Financial Metrics
Key Facts
- Total product revenue $125.5M in Q3 2026, up 19% YoY from $105.5M
- IBSRELA revenue $96.3M, up 23% YoY; XPHOZAH revenue $29.2M, up 7% YoY
- Net loss $0.7M ($0.00 per share) vs $1.0M ($0.00 per share) a year ago
- Cash and investments $285.3M as of Sep 30, 2026, up from $264.7M at Dec 31, 2025
- Full-year 2026 IBSRELA revenue guidance reiterated at $350M-$370M; XPHOZAH at $110M-$120M
- Phase 3 ACCEL trial for CIC fully enrolled; topline data expected H2 2027
- USPTO to issue patent covering commercial formulations of IBSRELA and XPHOZAH with expiration Dec 6, 2041
Financial Impact
Product revenue $125.5M, net loss $0.7M, cash $285.3M
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| IBSRELA | $96.3M | +23.0% |
| XPHOZAH | $29.2M | +7.0% |
Risk Factors
- Reiterated guidance implies no acceleration in H2 2026 vs consensus expectations
- R&D and SG&A expenses increased 39% and 12% YoY respectively, pressuring margins
- Phase 3 ACCEL trial results not expected until H2 2027, limiting near-term catalysts
- Competition from generic and branded IBS-C and hyperphosphatemia therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3394744 |
Track record
20 reports on ARDX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 17, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 5, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.99 Now $3.18 +6.35% settles Feb 3
- Nov 3, 202614d ago 8-K Neutral 4/10 No price data
- Nov 3, 202614d ago Press Release Neutral 4/10 Viewing Entry $3.29 Now $3.18 −3.34% settles Feb 2
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $3.39 Now $3.18 −6.19% settles Dec 30
- Aug 25, 202611w ago Insider Cluster Neutral 2/10 Entry $3.83 Now $3.18 −16.97% settles Nov 19
- Aug 25, 202611w ago Insider Cluster Neutral 2/10 Entry $3.83 Now $3.18 −16.97% settles Nov 19
- Aug 21, 202612w ago 144 Neutral 2/10 Entry $3.74 to $3.18 Now $3.18 −14.97% ▼ −14.97% −10.91% vs SPY
- Aug 21, 202612w ago 144 Neutral 2/10 Entry $3.74 to $3.18 Now $3.18 −14.97% ▼ −14.97% −10.91% vs SPY
- Aug 17, 202613w ago 8-K Neutral 2/10 Entry $3.92 to $3.01 Now $3.18 −18.88% ▼ −23.21% −21.17% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers